Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acorda Therapeutics
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of a stable sensorimotor deficit due to an ischemic stroke, as confirmed by the Investigator with supportive prior imaging findings (MRI/ CT scan)
≥ 6 months post-stroke
Have a body mass index (BMI) ranging between 18.0 - 35.0 kg/m,2 inclusive
Stable concomitant medication therapy regimen within 4 weeks of screening visit
You may not be if
History of seizures, except simple febrile seizures
Moderate or severe renal impairment as defined by a calculated creatinine clearance of ≤ 50 mL/minute using the Cockcroft-Gault Equation
Botulinum toxin use within 2 months prior to the Screening Visit
Orthopedic surgical procedures in any of the extremities within the past 6 months
Diagnosis of multiple sclerosis
Clareo Health | A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
